- Home
- IPSC vs INZY Comparison
IPSC vs INZY Comparison
Compare IPSC & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- INZY
- Stock Information
- Founded
- IPSC 2019
- INZY 2015
- Country
- IPSC United States
- INZY United States
- Employees
- IPSC N/A
- INZY N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- INZY Health Care
- Exchange
- IPSC Nasdaq
- INZY Nasdaq
- Market Cap
- IPSC 146.2M
- INZY 165.1M
- IPO Year
- IPSC 2021
- INZY 2020
- Fundamental
- Price
- IPSC $1.10
- INZY $2.94
- Analyst Decision
- IPSC Strong Buy
- INZY Strong Buy
- Analyst Count
- IPSC 4
- INZY 7
- Target Price
- IPSC $13.00
- INZY $16.14
- AVG Volume (30 Days)
- IPSC 864.2K
- INZY 920.5K
- Earning Date
- IPSC 11-05-2024
- INZY 11-05-2024
- Dividend Yield
- IPSC N/A
- INZY N/A
- EPS Growth
- IPSC N/A
- INZY N/A
- EPS
- IPSC N/A
- INZY N/A
- Revenue
- IPSC $2,684,000.00
- INZY N/A
- Revenue This Year
- IPSC $230.56
- INZY N/A
- Revenue Next Year
- IPSC $31.85
- INZY N/A
- P/E Ratio
- IPSC N/A
- INZY N/A
- Revenue Growth
- IPSC 7.88
- INZY N/A
- 52 Week Low
- IPSC $0.98
- INZY $2.39
- 52 Week High
- IPSC $5.51
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- IPSC 36.74
- INZY 39.38
- Support Level
- IPSC $0.98
- INZY $2.65
- Resistance Level
- IPSC $1.74
- INZY $3.28
- Average True Range (ATR)
- IPSC 0.14
- INZY 0.25
- MACD
- IPSC -0.04
- INZY 0.07
- Stochastic Oscillator
- IPSC 15.79
- INZY 39.07
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.